Astec Lifesciences Q2 FY27 Results: Consolidated Net Loss ₹37.40 Crore on Total Income of ₹72.64 Crore

Earnings
agrochemicals

Blacklitt Research26 October 20263 min read

A chemical plant at night, with illuminated process towers, pipework and steam rising from stacks. — Rjendrzejewski, via Wikimedia Commons (CC0). Illustrative image.

Astec Lifesciences (NSE: ASTEC) reported consolidated total income of ₹72.64 crore and a net loss of ₹37.40 crore for the quarter ended 30 Sep 2026, it said in a filing on 26 Oct 2026. Standalone total income was ₹72.62 crore and the standalone net loss was ₹37.43 crore.

Key highlights

Consolidated

Including its subsidiaries

Total income: ₹72.64 crore, down 2.9% YoY and 13.8% QoQ
Net profit and EPS: Net loss of ₹37.40 crore; basic EPS of (₹16.79)
Finance costs: ₹7.07 crore, down 15.8% YoY and 9.7% of total income

Standalone

The company on its own, without its subsidiaries

Total income: ₹72.62 crore, down 2.9% YoY and 13.8% QoQ
Net profit and EPS: Net loss of ₹37.43 crore; basic EPS of (₹16.80)
Finance costs: ₹7.08 crore, down 15.8% YoY and 9.7% of total income

Summary

Consolidated ₹ crore
Particulars	Q2 FY27	Q2 FY26	YoY	Q1 FY27	QoQ
	72.64	74.84	-2.9%	84.29	-13.8%
Revenue from operations	72.02	73.72	-2.3%	83.56	-13.8%
Other income	0.62	1.12	-44.8%	0.73	-15.3%
	-37.40	-24.42	-53.2%	-18.71	-99.9%
Profit before tax	-37.43	-24.41	-53.3%	-18.74	-99.7%
Finance costs	7.07	8.40	-15.8%	7.73	-8.6%
Depreciation	11.18	10.44	+7.1%	11.07	+1.0%
Tax expense	-0.03	0.01	n/a	-0.03	+0.6%
Net profit margin	-51.49%	-32.63%	-18.86 pp	-22.19%	-29.29 pp
EPS, basic (₹)	-16.79	-11.35	-47.9%	-8.40	-99.9%

Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

Revenue fell and the loss widened. Revenue from operations of ₹72.02 crore was 2.3% lower than a year earlier, and other income fell 44.8% to ₹0.62 crore, so total income declined 2.9%. The net loss rose 53.2% to ₹37.40 crore.

Loss before tax went from ₹24.41 crore to ₹37.43 crore. The quarter carries a tax credit of ₹0.03 crore, against a tax charge of ₹0.01 crore a year earlier, so the net loss is ₹0.03 crore smaller than the pre-tax loss.

Finance costs fell 15.8% to ₹7.07 crore, which is 9.7% of total income. Depreciation rose 7.1% to ₹11.18 crore and is larger than finance costs.

Net worth stood at ₹335.10 crore at 30 Sep 2026, with non-current borrowings of ₹30.00 crore and current borrowings of ₹300.50 crore, a debt equity ratio of 0.99 times. The statement shows no exceptional item for the quarter; the ₹2.09 crore exceptional item relates to the year ended 31 Mar 2026 and the four Labour Codes, which the company calls materially regulatory-driven and non-recurring.

Standalone ₹ crore
Particulars	Q2 FY27	Q2 FY26	YoY	Q1 FY27	QoQ
	72.62	74.81	-2.9%	84.27	-13.8%
Revenue from operations	72.02	73.72	-2.3%	83.56	-13.8%
Other income	0.60	1.09	-45.4%	0.71	-15.7%
	-37.43	-24.45	-53.1%	-18.74	-99.7%
Profit before tax	-37.47	-24.45	-53.2%	-18.78	-99.5%
Finance costs	7.08	8.41	-15.8%	7.74	-8.5%
Depreciation	11.20	10.46	+7.1%	11.09	+1.0%
Tax expense	-0.04	0.00	n/a	-0.04	0.0%
Net profit margin	-51.54%	-32.68%	-18.86 pp	-22.24%	-29.31 pp
EPS, basic (₹)	-16.80	-11.39	-47.5%	-8.41	-99.8%

Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

Standalone total income of ₹72.62 crore is 2.9% lower than a year earlier, and the net loss of ₹37.43 crore is 53.1% wider. Standalone other income fell 45.4% to ₹0.60 crore, and revenue from operations fell 2.3%.

The standalone result carries a tax credit of ₹0.04 crore, against nil a year earlier. The consolidated loss is ₹0.03 crore smaller than the standalone loss. The consolidated figures include subsidiaries listed in the auditors' annexure, and one subsidiary whose interim information was not reviewed is stated as not material to the group.

Inference

The filing says the company's commercial papers are listed on the National Stock Exchange. ICRA has assigned [ICRA] A1+ to short term facilities including commercial paper and [ICRA] AA- to long term facilities, and India Ratings & Research has assigned [IND] AA- to non-convertible debentures. The statutory auditors, BSR & Co. LLP, gave unmodified conclusions on both sets of results.

The board approved the results on 26 Oct 2026. The filing does not say whether any dividend is proposed or declared for the period, nor how the company plans to meet its ₹300.50 crore of current borrowings.

Reference: Original filing (PDF)

Sign up to continue reading

Create a free account to read the rest of this article and the analysis that follows.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.